The Korea Economic Daily reports that Novo Holdings, the controlling shareholder of Novo Nordisk, is treating Korea as a key market for healthcare investment in Asia.
Recap by typeshit. Post by The Korea Economic Daily on X.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
An opinion piece drawing on Sabrina Strings to tie GLP-1 culture, celebrity ads and Ozempic-friendly menus to class and belonging.
8:58
Constable, who bills herself as a peptide expert, lists side effects she links to the unapproved triple agonist. Her claims, not trial data, so weigh them accordingly.
Loading…